Henan Cancer Hospital: Lymphoma trials

The registry lists 15 Lymphoma studies with Henan Cancer Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• L218CAR19 in Patients With Relapsed/Refractory B-cell LymphomaRecruitingNCT06478381Phase 1
• This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
• The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06160362Not applicable
• Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
• Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
• Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
• Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
• Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
• Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in LymphomaRecruitingNCT04263935
• Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
• Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell MalignanciesStatus unknownNCT03881774Phase 1
• CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell LymphomaStatus unknownNCT03881761Phase 1
• Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell LymphomaStatus unknownNCT03540303Phase 1
• The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaStatus unknownNCT03101709Phase 1
• Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaStatus unknownNCT02733380Phase 2